All PlansAdministrativeMedium impact
08.00.84m, Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris®) for intravenous administration
Independence Blue Cross·Pharmacy
We identified it
Jul 9, 2026
Summary
Failed to analyze policy change